White Papers

White Paper

The Inspection Readiness Playbook for GMP Manufacturing

Inspection readiness fails for boringly predictable reasons. The documentation is technically complete but nobody can retrieve it under pressure. Subject matter experts have never been asked a hard question by someone outside the company. Open CAPAs tell a story the site would rather not tell.

The playbook works through the twelve weeks before an inspection, then the practices that decide how the day itself goes: front room and back room discipline, document retrieval drills, and how to prepare an SME who has never sat across from an investigator. There is a readiness assessment at the back you can run yourself, before deciding whether you need help from outside at all.

• Quality and Compliance
• Pharmaceutical and Biotechnology

White Paper

Staffing a Phase III Program Without Losing Timeline

A Phase III program rarely slips because one role went unfilled. It slips because the roles were filled in the wrong order. Data management arrives after database lock is already at risk. Medical writing gets engaged once the submission clock has started running.

This one maps the resourcing sequence against clinical milestones: which functions have to be in place before study startup, and which can be layered in later without much disruption. It draws on engagements where sponsors went from a handful of contributors to teams of twenty or more.

Most of the damage is done in the first six weeks.

• Life Sciences Staffing
• Clinical Operations

White Paper

EU MDR Technical Documentation Remediation

Legacy technical files written under the MDD rarely survive first contact with an MDR review. Clinical evaluation is thin. Post-market surveillance is retrospective. The safety and performance requirements matrix was assembled once, years ago, and never opened again.

The paper breaks remediation into work packages that can run in parallel across a portfolio, with guidance on the triage question everyone gets stuck on: which device families need a full rewrite, and which just need targeted evidence. Teams who have already had a deficiency letter tend to skip to the sequencing section.

• Medical Devices
• Regulatory Affairs

White Paper

Data Integrity in GxP Systems: Beyond the Audit Trail

Most data integrity remediation goes after systems. Audit trails get switched on, access controls get tightened, the finding closes. Two years later the same observation comes back, because the problem was never a technical one.

This paper looks at where data integrity breaks down in practice: the handoff between analyst and reviewer, the second-person review nobody has time to do properly, and the paper records that quietly shadow a validated system. It covers assessment, the order to remediate in, and how to show an investigator sustained control rather than a fix that happened to be in place on the day.

• Quality and Compliance
• Pharmaceutical and Biotechnology

White Paper

Direct Sourcing for Specialized Life Sciences Talent

Direct sourcing gets pitched as a cost play. For repeatable, high-volume roles that is broadly true. For a CMC analytical scientist with a specific platform background, your curated pool will sit empty while the program waits on it.

The paper separates the roles where direct sourcing works from the ones where it quietly adds cycle time, and sets out what has to sit behind a working program: employer brand, a nurture cadence somebody owns, and somewhere for people to go when a contract ends.

That last one is where most programs come apart.

• Contingent Workforce Solutions
• Life Sciences Staffing

White Paper

Preparing a BLA Submission Team

A BLA is a document control problem wearing a science costume. The science is usually settled months before filing. What slips is authoring capacity, review cycles, and the publishing work nobody scoped because it did not look like work.

The paper covers how to structure a submission team across regulatory, medical writing, CMC, and publishing, and the review cadence that keeps modules moving in parallel instead of one after another. It is aimed at a first or second filing, where there is no institutional memory to fall back on.

• Regulatory Affairs
• Pharmaceutical and Biotechnology